<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922812460913</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922812460913</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serial Procalcitonin Levels to Detect Bacteremia in Febrile Neutropenia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Reitman</surname><given-names>Aaron J.</given-names></name>
<degrees>DO</degrees>
<xref ref-type="aff" rid="aff1-0009922812460913">1</xref>
<xref ref-type="aff" rid="aff2-0009922812460913">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pisk</surname><given-names>Rhonda M.</given-names></name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-0009922812460913">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gates</surname><given-names>John V.</given-names><suffix>III</suffix></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812460913">1</xref>
<xref ref-type="aff" rid="aff2-0009922812460913">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ozeran</surname><given-names>J. Daniel</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0009922812460913">1</xref>
<xref ref-type="aff" rid="aff2-0009922812460913">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922812460913"><label>1</label>University of California, San Francisco-Fresno, Fresno, CA, USA</aff>
<aff id="aff2-0009922812460913"><label>2</label>Children’s Hospital Central California, Madera, CA, USA</aff>
<author-notes>
<corresp id="corresp1-0009922812460913">Aaron J. Reitman, Children’s Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027 Email: <email>Aaron@DrReitman.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>51</volume>
<issue>12</issue>
<fpage>1175</fpage>
<lpage>1183</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>. Our objective was to evaluate serial procalcitonin (PCT) levels compared with an initial PCT level at admission in predicting bacteremia in pediatric febrile neutropenic oncology patients. <italic>Procedure</italic>. Serum PCT levels were measured at admission (t0) and within 24 hours of admission (t1) in pediatric oncology patients presenting with fever and neutropenia. A blood culture was collected at t0 and monitored for 5 days for bacterial growth. PCT value of 0.5 ng/mL at either t0 or t1 was considered predictive for bacteremia. <italic>Results</italic>. PCT levels were significantly higher in children with positive blood cultures than with negative blood cultures. Serial PCT values mirrored t1 values. Serial PCT showed 76% specificity and negative predictive value of 93% in ruling out bacteremia. <italic>Conclusion</italic>. Elevated PCT levels are predictive of bacteremia. Using serial PCT levels within 24 hours allowed a better prediction of bacteremia than the PCT level at t0.</p>
</abstract>
<kwd-group>
<kwd>procalcitonin</kwd>
<kwd>febrile</kwd>
<kwd>neutropenia</kwd>
<kwd>oncology</kwd>
<kwd>pediatric</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0009922812460913" sec-type="intro">
<title>Introduction</title>
<p>This article reports on a small-to-medium sized, prospective, single-center study on the prediction of bacteremia by serial procalcitonin (PCT) measurements in children with fever and chemotherapy-induced neutropenia. Patients undergoing chemotherapy for cancer will have periods of neutropenia, and during these times, febrile patients are at a higher risk for developing bacteremia.<sup><xref ref-type="bibr" rid="bibr1-0009922812460913">1</xref></sup></p>
<p>Over the past 3 decades, clinicians have attempted to identify children with fever and neutropenia to be at either high or low risk for a serious bacterial infection. The hopes of risk classification were to decrease the rate of hospital admissions, to prevent the emergence of antimicrobial resistance,<sup><xref ref-type="bibr" rid="bibr2-0009922812460913">2</xref></sup> to avoid in-hospital complications, and to decrease the impairment of quality of life to patients and their families. Oncologists have categorized high- and low-risk adult patients for the development of bacteremia, but their recommendations have been limited.<sup><xref ref-type="bibr" rid="bibr3-0009922812460913">3</xref><xref ref-type="bibr" rid="bibr4-0009922812460913"/><xref ref-type="bibr" rid="bibr5-0009922812460913"/>-<xref ref-type="bibr" rid="bibr6-0009922812460913">6</xref></sup> Similarly, high- and low-risk classification studies have been evaluated in pediatric patients. Even though there have been retrospective,<sup><xref ref-type="bibr" rid="bibr7-0009922812460913">7</xref><xref ref-type="bibr" rid="bibr8-0009922812460913"/><xref ref-type="bibr" rid="bibr9-0009922812460913"/><xref ref-type="bibr" rid="bibr10-0009922812460913"/><xref ref-type="bibr" rid="bibr11-0009922812460913"/><xref ref-type="bibr" rid="bibr12-0009922812460913"/><xref ref-type="bibr" rid="bibr13-0009922812460913"/>-<xref ref-type="bibr" rid="bibr14-0009922812460913">14</xref></sup> prospective,<sup><xref ref-type="bibr" rid="bibr15-0009922812460913">15</xref><xref ref-type="bibr" rid="bibr16-0009922812460913"/><xref ref-type="bibr" rid="bibr17-0009922812460913"/><xref ref-type="bibr" rid="bibr18-0009922812460913"/>-<xref ref-type="bibr" rid="bibr19-0009922812460913">19</xref></sup> and validation studies<sup><xref ref-type="bibr" rid="bibr20-0009922812460913">20</xref></sup> for high- and low-risk patients, the majority of the pediatric oncologists have been slow to adapt risk classifications for serious bacterial infections in this high-risk population.</p>
<p>Regardless of risk, pediatric patients undergoing chemotherapy continue to be routinely hospitalized for fever and neutropenia. The current treatment consensus for fever and neutropenia in pediatric patients has been hospital admission, initiation of broad-spectrum antibiotics, and maintenance until the blood culture results are negative for bacterial growth.<sup><xref ref-type="bibr" rid="bibr21-0009922812460913">21</xref></sup> Kara et al<sup><xref ref-type="bibr" rid="bibr22-0009922812460913">22</xref></sup> showed that pediatric blood cultures may not produce growth for the first 48 hours. Their study had bacterial growth in 54% of children by day 3, 77% by day 4, and 89% by day 5.<sup><xref ref-type="bibr" rid="bibr22-0009922812460913">22</xref></sup> Furthermore, even when the clinical picture depicts a patient who is septic, the blood culture may not produce bacterial growth.<sup><xref ref-type="bibr" rid="bibr23-0009922812460913">23</xref></sup> Several studies have shown this to be evident in pediatric patients because the blood volume obtained is inadequate for bacterial growth.<sup><xref ref-type="bibr" rid="bibr22-0009922812460913">22</xref>,<xref ref-type="bibr" rid="bibr24-0009922812460913">24</xref>,<xref ref-type="bibr" rid="bibr25-0009922812460913">25</xref></sup> On the contrary, blood cultures are widely known to have false positives. Although blood cultures are not perfect, it is still the gold standard for detecting bacteremia.</p>
<p>Because blood cultures can be affected by skin preparation, the number and timing of blood draws, the appropriate volume of blood for culture, the culture media and additives, length and atmosphere of incubation, and interpretation of positive blood culture results,<sup><xref ref-type="bibr" rid="bibr25-0009922812460913">25</xref></sup> investigators have attempted to use biomarkers to help early identify serious bacterial infections. The most widely used biomarker is C-reactive protein, but interleukin-6, -8, and -10, neopterin, and tumor necrosis factor-α have also been investigated.<sup><xref ref-type="bibr" rid="bibr26-0009922812460913">26</xref><xref ref-type="bibr" rid="bibr27-0009922812460913"/><xref ref-type="bibr" rid="bibr28-0009922812460913"/><xref ref-type="bibr" rid="bibr29-0009922812460913"/>-<xref ref-type="bibr" rid="bibr30-0009922812460913">30</xref></sup> Even though C-reactive protein has shown some promise detecting bacteremia in immunocompromised pediatric hosts, there is still a need for a more sensitive and specific biomarker for detecting bacteremia.</p>
<p>Procalcitonin is a polypeptide composed of 116 amino acids and is the prohormone of calcitonin. In healthy patients, it is barely detectable and primarily found in the thyroid.<sup><xref ref-type="bibr" rid="bibr31-0009922812460913">31</xref></sup> During a serious bacterial infection, PCT is rapidly produced by multiple organ systems and can be easily detected in blood serum.<sup><xref ref-type="bibr" rid="bibr31-0009922812460913">31</xref>,<xref ref-type="bibr" rid="bibr32-0009922812460913">32</xref></sup> This makes PCT a unique tool for the detection of bacteremia in patients, even those who are neutropenic.</p>
<p>Recently in a large review of PCT, Reinhart and Meisner<sup><xref ref-type="bibr" rid="bibr33-0009922812460913">33</xref></sup> showed that PCT can be used reliably in adult patients for the early detection of serious bacterial infections, sepsis, and septic shock. Sakr et al<sup><xref ref-type="bibr" rid="bibr34-0009922812460913">34</xref></sup> demonstrated that elevated PCT levels can aid in the early detection of bacteremia and sepsis in the adult febrile neutropenic population. There have been limited investigations on the use of PCT in children with fever and chemotherapy-induced neutropenia, which showed that it was a reliable biomarker to detect serious bacterial infections.<sup><xref ref-type="bibr" rid="bibr19-0009922812460913">19</xref>,<xref ref-type="bibr" rid="bibr27-0009922812460913">27</xref><xref ref-type="bibr" rid="bibr28-0009922812460913"/><xref ref-type="bibr" rid="bibr29-0009922812460913"/>-<xref ref-type="bibr" rid="bibr30-0009922812460913">30</xref>,<xref ref-type="bibr" rid="bibr35-0009922812460913">35</xref><xref ref-type="bibr" rid="bibr36-0009922812460913"/><xref ref-type="bibr" rid="bibr37-0009922812460913"/><xref ref-type="bibr" rid="bibr38-0009922812460913"/>-<xref ref-type="bibr" rid="bibr39-0009922812460913">39</xref></sup> In a small study, Barnes et al<sup><xref ref-type="bibr" rid="bibr40-0009922812460913">40</xref></sup> evaluated the delta PCT level in children with fever and neutropenia to predict the length of admission. Barnes et al<sup><xref ref-type="bibr" rid="bibr40-0009922812460913">40</xref></sup> concluded that patients with a rise in PCT of 0.2 ng/mL within 24 hours had a higher probability of being hospitalized greater than 5 days. Although PCT levels in adults for serious bacterial infections are known to be greater than 0.5 ng/mL, there is a paucity of data in children.<sup><xref ref-type="bibr" rid="bibr41-0009922812460913">41</xref></sup> This is a prospective study to compare a single PCT level to serial PCT levels for the early detection of bacteremia in children with chemotherapy-induced neutropenia using a highly sensitive automated PCT analyzer.</p>
</sec>
<sec id="section2-0009922812460913" sec-type="methods">
<title>Methods</title>
<sec id="section3-0009922812460913">
<title>Settings and Participants</title>
<p>This study was conducted at Children’s Hospital Central California (CHCC), and the study received approval by the local institutional review board. The study was granted a waiver of informed consent. CHCC is an academic and tertiary freestanding pediatric hospital that has approximately 150 new cancer diagnoses per year. The CHCC oncology clinic has 7 physicians who oversee almost 6500 patient encounters per year. The study took place over an 11-month period (January 1, 2009, to November 30, 2009). Patients between the ages of 3 months and 18 years who had a defined cancer diagnosis denoted with an <italic>ICD-9</italic> code between 140.0 and 208.9 were eligible for participation in this study.<sup><xref ref-type="bibr" rid="bibr42-0009922812460913">42</xref></sup> Patients with fever and suspected neutropenia were included in the study. Moreover, patients with multiple episodes of fever and neutropenia on different admissions were allowed to be included in this study. To isolate the most susceptible patient population, the final study population included only those participants with an absolute neutrophil count (ANC) less than 500 cells/mm<sup>3</sup> and a documented fever greater than 38°C.</p>
</sec>
<sec id="section4-0009922812460913">
<title>Specific Aims</title>
<p>The principal objective of this study was to test the diagnostic performance of serial PCT levels in predicting bacteremia in pediatric oncology patients with fever and neutropenia using a highly sensitive assay. A secondary objective was to determine if there was an optimal cutoff PCT level in predicting bacteremia.</p>
</sec>
<sec id="section5-0009922812460913">
<title>Design</title>
<p>A prospective cohort study was conducted at a tertiary pediatric hospital. Our patient population included oncology patients with fever and suspected neutropenia. These patients were either neutropenic secondary to chemotherapy or as a result of their underlying disease process. Serum PCT levels were measured at admission (t0) and within 12 to 24 hours of the t0 draw (t1) from blood collected as part of routine clinical care. At t0, a blood culture was collected from either a central line or from a peripheral vein. Blood cultures were monitored for 5 days and were considered positive for bacterial growth if detected within 48 hours of collection.</p>
<p>For patients who were enrolled in the study, the following information was collected prospectively: (<italic>a</italic>) date and time of lab draws, (<italic>b</italic>) complete blood count with manual ANC (t0), (<italic>c</italic>)blood culture results (t0), (<italic>d</italic>) viral testing results, (<italic>e</italic>) radiographs, and (<italic>f</italic>)stool studies if clinically indicated. Blood samples for PCT testing were obtained from specimens remaining after routine clinical testing drawn at an inpatient or outpatient encounter. Samples were frozen at −20°C and analyzed for PCT levels at a later time by the research team. PCT results were blinded to clinical staff and only available to the researchers for analysis. In this investigation, PCT values were neither compared with the absolute monocyte count nor with the vital signs excluding temperature.</p>
</sec>
<sec id="section6-0009922812460913">
<title>Definitions</title>
<p>Neutropenia was defined as an ANC less than 500 cells/mm<sup>3</sup> of blood. Fever was defined as a single body temperature greater than 38°C at home and/or in the hospital. Fevers associated with blood product infusions were excluded. A PCT level ≥0.5 ng/mL at either t0 or t1 was considered a positive result, whereas a PCT level &lt;0.5 ng/mL at either t0 or t1 was considered a negative result.</p>
</sec>
<sec id="section7-0009922812460913">
<title>Procalcitonin Measurements</title>
<p>PCT samples were analyzed on a KRYPTOR machine (BRAHMS International/Thermo Fischer Scientific, Berlin, Germany). KRYPTOR uses TRACE (Time Resolved Amplified Cryptate Emission) technology to detect PCT levels in serum samples. The KRYPTOR assay is specific for PCT. It is based on a polyclonal anti-calcitonin antibody and a monoclonal anti-katacalcin antibody that binds to the calcitonin and katacalcin sequences of procalciton, respectively. Then using a nonradiative transfer of energy between the 2 fluorescent tracers the signal was measured.</p>
<p>The signal measured during the formation of the antigen–antibody complex signal is proportional to the amount of PCT. The testing required a minimum of 20 mL serum, and results were obtained in approximately 20 minutes.<sup><xref ref-type="bibr" rid="bibr41-0009922812460913">41</xref></sup></p>
</sec>
<sec id="section8-0009922812460913">
<title>Analysis</title>
<p>All statistical analyses were completed using Predictive Analytics Software, version 18.0.0 (PASW; IBM SPSS, Chicago, IL). Descriptive statistics were evaluated to determine mean age and mean PCT values. Statistical comparisons were performed using <italic>t</italic> tests and χ<sup>2</sup> tests to determine the impact of PCT testing on the patient population. Sensitivity and specificity were calculated as well as negative predicative values (NPVs) and positive predicative values (PPVs). Sensitivity was calculated as the number of correctly identified patients with bacterial illness divided by all positive blood cultures; specificity was calculated as the number of correctly identified nonbacterial illness patients divided by all the negative blood cultures. The PPV is the probability that a patient with a positive PCT test result (PCT &gt;0.5 ng/mL) has a bacterial illness. The NPV is the probability that a patient with negative PCT test result (PCT ≤0.5 ng/mL) is truly not bacteremic. The diagnostic property of PCT was investigated by receiver operating characteristic (ROC) analysis. <italic>P</italic> &lt; .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section9-0009922812460913" sec-type="results">
<title>Results</title>
<sec id="section10-0009922812460913">
<title>Population and Blood Cultures Results</title>
<p>During the 11-month study period, a total of 223 febrile encounters occurred in 129 pediatric oncology patients who were presumed to have neutropenia. Of these, 127 encounters were excluded because of ANC &gt;500 (n = 52 patients). An additional 7 patients who did not have 2 serial PCT levels analyzed were also excluded. A total of 89 febrile neutropenic encounters in 70 patients who met all study inclusion and exclusion criteria were included in this study for analysis (<xref ref-type="fig" rid="fig1-0009922812460913">Figure 1</xref>). Of the 89 encounters studied (mean age = 8.6 years, SD = 5.2), 20% (n = 18 patients) had positive blood cultures. The mean ANC for the eligible encounters was 111 with a standard deviation of 133 (range = 0-438). All blood cultures were followed for 5 days. No blood culture showed bacterial growth after 48 hours.</p>
<fig id="fig1-0009922812460913" position="float">
<label>Figure 1.</label>
<caption>
<p>Patient flow diagram</p>
</caption>
<graphic xlink:href="10.1177_0009922812460913-fig1.tif"/>
</fig>
</sec>
<sec id="section11-0009922812460913">
<title>Comparison of Blood Culture Results and PCT Values</title>
<p>Combined analysis of 178 PCT levels (89 febrile neutropenic encounters) at both time points yielded significantly higher mean PCT levels in participants with a positive blood culture than with a negative blood culture (7.84, 0.63, <italic>P</italic> &lt; .0001), respectively. When comparing patients with positive and negative blood cultures at the 2 time points, the elevation in PCT levels was more apparent (<xref ref-type="table" rid="table1-0009922812460913">Table 1</xref>).</p>
<table-wrap id="table1-0009922812460913" position="float">
<label>Table 1.</label>
<caption>
<p>Evaluation of Procalcitonin at 2 Time Points<sup><xref ref-type="table-fn" rid="table-fn2-0009922812460913">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0009922812460913" xlink:href="10.1177_0009922812460913-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Mean PCT<hr/></th>
<th/>
</tr>
<tr>
<th/>
<th align="center">t0 (ng/mL)</th>
<th align="center">t1 (ng/mL)</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacteremic</td>
<td>4.090</td>
<td>11.600</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Nonbacteremic</td>
<td>0.542</td>
<td>0.715</td>
<td>.22</td>
</tr>
<tr>
<td><italic>P</italic></td>
<td>.001</td>
<td>.0001</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0009922812460913">
<p>Abbreviations: PCT, procalcitonin; t0, PCT draw at admission; t1, PCT second draw.</p>
</fn>
<fn id="table-fn2-0009922812460913">
<label>a</label>
<p>Serial results mirror t1 results.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Serial PCT draws were analyzed to evaluate the number of patients that exhibited PCT variability between t0 and t1 (<xref ref-type="table" rid="table2-0009922812460913">Table 2</xref>). A serial PCT level greater than 0.5 ng/mL at either t0 or t1 was considered predictive for bacteremia, whereas a PCT level less than 0.5 ng/mL at both t0 and t1 was considered a negative indicator of bacteremia. To analyze the usefulness of serial PCT draws, any patient with a positive PCT level at either t0 or t1 was considered positive. The diagnostic usefulness of PCT in this patient population was calculated (<xref ref-type="table" rid="table3-0009922812460913">Table 3</xref>). In this patient population, there were no patients with a positive PCT level at t0 and a negative PCT level at t1; thus, the results for t1 are identical to the results for serial PCT draws (<xref ref-type="table" rid="table2-0009922812460913">Tables 2</xref> and <xref ref-type="table" rid="table3-0009922812460913">3</xref>).</p>
<table-wrap id="table2-0009922812460913" position="float">
<label>Table 2.</label>
<caption>
<p>Serial Blood Draws</p>
</caption>
<graphic alternate-form-of="table2-0009922812460913" xlink:href="10.1177_0009922812460913-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">PCT Serial (t0/t1)</th>
<th align="center">Blood Culture Negative (n)</th>
<th align="center">Blood Culture Positive (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neg/Neg</td>
<td>54</td>
<td>4</td>
</tr>
<tr>
<td>Pos/Pos</td>
<td>15</td>
<td>9</td>
</tr>
<tr>
<td>Pos/Neg</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neg/Pos</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0009922812460913">
<p>Abbreviations: PCT, procalcitonin; t0, PCT draw at admission; t1, PCT second draw; Neg, negative PCT ≤0.5 ng/mL; Pos, positive PCT &gt;0.5 ng/mL.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0009922812460913" position="float">
<label>Table 3.</label>
<caption>
<p>Diagnostic Values at Different Cutoff Values to Predict Bacteremia</p>
</caption>
<graphic alternate-form-of="table3-0009922812460913" xlink:href="10.1177_0009922812460913-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Draw</th>
<th align="center">PCT Value</th>
<th align="center">Sensitivity (%)</th>
<th align="center">Specificity (%)</th>
<th align="center">NPV (%)</th>
<th align="center">PPV (%)</th>
<th align="center">Positive Likelihood Ratio (Weighted)</th>
<th align="center">Negative Likelihood Ratio (Weighted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draw 1 (t0)</td>
<td>0.2</td>
<td>78</td>
<td>49</td>
<td>90</td>
<td>28</td>
<td>0.39</td>
<td>0.11</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>72</td>
<td>65</td>
<td>90</td>
<td>34</td>
<td>0.52</td>
<td>0.11</td>
</tr>
<tr>
<td/>
<td>0.4</td>
<td>72</td>
<td>70</td>
<td>91</td>
<td>38</td>
<td>0.62</td>
<td>0.10</td>
</tr>
<tr>
<td/>
<td>0.5</td>
<td>50</td>
<td>79</td>
<td>86</td>
<td>38</td>
<td>0.60</td>
<td>0.16</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>44</td>
<td>89</td>
<td>86</td>
<td>50</td>
<td>1.0</td>
<td>0.16</td>
</tr>
<tr>
<td/>
<td>2</td>
<td>22</td>
<td>94</td>
<td>83</td>
<td>48</td>
<td>1.0</td>
<td>0.21</td>
</tr>
<tr>
<td/>
<td>5</td>
<td>22</td>
<td>99</td>
<td>83</td>
<td>85</td>
<td>4.0</td>
<td>0.20</td>
</tr>
<tr>
<td>Draw 2 (t1)</td>
<td>0.2</td>
<td>100</td>
<td>45</td>
<td>100</td>
<td>31</td>
<td>0.46</td>
<td>&lt;0.00</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>89</td>
<td>56</td>
<td>95</td>
<td>34</td>
<td>0.52</td>
<td>0.05</td>
</tr>
<tr>
<td/>
<td>0.4</td>
<td>89</td>
<td>68</td>
<td>96</td>
<td>41</td>
<td>0.70</td>
<td>0.04</td>
</tr>
<tr>
<td/>
<td>0.5</td>
<td>78</td>
<td>76</td>
<td>93</td>
<td>45</td>
<td>0.82</td>
<td>0.07</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>67</td>
<td>86</td>
<td>91</td>
<td>55</td>
<td>1.2</td>
<td>0.10</td>
</tr>
<tr>
<td/>
<td>2</td>
<td>61</td>
<td>92</td>
<td>90</td>
<td>66</td>
<td>1.8</td>
<td>0.11</td>
</tr>
<tr>
<td/>
<td>5</td>
<td>44</td>
<td>97</td>
<td>87</td>
<td>79</td>
<td>4.0</td>
<td>0.14</td>
</tr>
<tr>
<td>Serial<sup><xref ref-type="table-fn" rid="table-fn5-0009922812460913">a</xref></sup></td>
<td>0.2</td>
<td>100</td>
<td>45</td>
<td>100</td>
<td>31</td>
<td>0.46</td>
<td>&lt;0.00</td>
</tr>
<tr>
<td/>
<td>0.3</td>
<td>89</td>
<td>56</td>
<td>95</td>
<td>34</td>
<td>0.52</td>
<td>0.05</td>
</tr>
<tr>
<td/>
<td>0.4</td>
<td>89</td>
<td>68</td>
<td>96</td>
<td>41</td>
<td>0.70</td>
<td>0.04</td>
</tr>
<tr>
<td/>
<td>0.5</td>
<td>78</td>
<td>76</td>
<td>93</td>
<td>45</td>
<td>0.82</td>
<td>0.07</td>
</tr>
<tr>
<td/>
<td>1</td>
<td>67</td>
<td>86</td>
<td>91</td>
<td>55</td>
<td>1.2</td>
<td>0.10</td>
</tr>
<tr>
<td/>
<td>2</td>
<td>61</td>
<td>92</td>
<td>90</td>
<td>66</td>
<td>1.8</td>
<td>0.11</td>
</tr>
<tr>
<td/>
<td>5</td>
<td>44</td>
<td>97</td>
<td>87</td>
<td>79</td>
<td>4.0</td>
<td>0.14</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0009922812460913">
<p>Abbreviations: PCT, procalcitonin; t0, PCT draw at admission; t1, PCT second draw; NPV, negative predictive value; PPV, positive predictive value.</p>
</fn>
<fn id="table-fn5-0009922812460913">
<label>a</label>
<p>Serial results mirror t1 results.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>PCT levels at admission (t0) showed a sensitivity of 50% and a specificity of 79%. Analysis of serial PCT draws indicated a sensitivity of 78% and specificity of 76%. Serial PCT produced a negative predictive value of 96%, thus demonstrating it as a useful biomarker in ruling out bacteremia. Using the ROC curve analysis, the area under the curve (AUC) was determined at t0, t1, and serial draws (0.77, 0.88, and 0.88, respectively; <xref ref-type="fig" rid="fig2-0009922812460913">Figure 2</xref>). The AUC of 0.88 indicates serial PCT draws to be a better biomarker than a single PCT draw for bacteremia in this population.</p>
<fig id="fig2-0009922812460913" position="float">
<label>Figure 2.</label>
<caption>
<p>Receiver operating characteristic curve</p>
</caption>
<graphic xlink:href="10.1177_0009922812460913-fig2.tif"/>
</fig>
<p>The prevalence of bacteremia in the study population was 20% or 1 in 5 patients. Using the positive likelihood ratio, there is an 85% probability that the patients found to have a positive serial PCT result will have bacteremia. Likewise, the negative likelihood ratios can be used to determine that a patient with a negative serial PCT level has less than a 1% chance of having bacteremia. These results again suggest that PCT is a useful diagnostic test in this patient population (<xref ref-type="table" rid="table3-0009922812460913">Table 3</xref>).</p>
<p>In the attempt to establish the optimal PCT cutoff value to be used in our specific population, the diagnostic sensitivity and specificity of PCT were explored using the ROC results. The best combination of sensitivity and specificity in this population was achieved at a cutoff value of 0.4 ng/mL at both t0 and t1 time points.</p>
</sec>
</sec>
<sec id="section12-0009922812460913" sec-type="discussion">
<title>Discussion</title>
<p>Children undergoing chemotherapy for cancer will most certainly have episodes with fever and neutropenia during treatment. This association occurs with greater frequency with the growing intensity of chemotherapy. The rapid progression of bacterial infections in neutropenic pediatric patients to sepsis is one reason why these patients are frequently admitted to the hospital and broad-spectrum antibiotics are initiated.</p>
<p>The precise volume of blood needed to adequately detect bacteremia in children has not been established as in adults.<sup><xref ref-type="bibr" rid="bibr24-0009922812460913">24</xref>,<xref ref-type="bibr" rid="bibr43-0009922812460913">43</xref>,<xref ref-type="bibr" rid="bibr44-0009922812460913">44</xref></sup> Blood cultures may not yield bacterial growth for several days. Nonetheless, blood cultures are still considered the gold standard for the detection of bacteremia. The presence of a reliable sepsis marker could assist in clinical decision making.</p>
<p>In children presenting with fever and neutropenia, PCT has been shown to be a useful biomarker in detecting serious bacterial infections.<sup><xref ref-type="bibr" rid="bibr19-0009922812460913">19</xref>,<xref ref-type="bibr" rid="bibr27-0009922812460913">27</xref><xref ref-type="bibr" rid="bibr28-0009922812460913"/><xref ref-type="bibr" rid="bibr29-0009922812460913"/>-<xref ref-type="bibr" rid="bibr30-0009922812460913">30</xref>,<xref ref-type="bibr" rid="bibr35-0009922812460913">35</xref><xref ref-type="bibr" rid="bibr36-0009922812460913"/><xref ref-type="bibr" rid="bibr37-0009922812460913"/><xref ref-type="bibr" rid="bibr38-0009922812460913"/>-<xref ref-type="bibr" rid="bibr39-0009922812460913">39</xref></sup> This study confirms the results from previous studies as well as demonstrates the importance of serial PCT levels in the detection of bacteremia. This study showed serial PCT draws to be better at detecting bacteremia than a single PCT level, with the average increase in sensitivity between t0 and t1 being 24%. However, the specificity of serial PCT draws in our study population was affected by the large number of febrile and neutropenic episodes (n = 15) that showed no bacterial growth and had positive PCT levels at both t0 and t1. By including a second PCT draw (t1), 5 out of 7 patients who were initially negative for PCT (at t0) had a positive PCT value at t1.</p>
<p>Four of our patient encounters showed bacterial organisms in the blood cultures even though both the draws showed PCT levels ≤0.5 ng/mL. The 4 identified organisms with negative PCT are the following: <italic>Capnocytophaga</italic> species (t0 = 0.18 ng/mL, t1 = 0.22 ng/mL), <italic>Streptococcus salivarius</italic> (t0 = 0.17 ng/mL, t1 = 0.45 ng/mL), <italic>Streptococcus mitis</italic> (t0 = 0.43 ng/mL, t1 = 0.28 ng/mL), and <italic>Escherichia coli</italic> (t0 = 0.19 ng/mL, t1 = 0.48). Of note, using the optimal PCT cutoff of 0.4 ng/mL would have raised suspicions about the latter 3 organisms. The patient encounter with blood culture positive for <italic>E coli</italic> (PCT &lt;0.5 ng/mL) did not correlate with 2 other encounters that grew <italic>E coli</italic> (mean PCT = 3.81 ng/mL at t0 and 7.50 ng/mL at t1).</p>
<p>In a post hoc analysis using a positive PCT &gt;0.5 ng/mL, we noticed patients with Gram-positive bacteremia (n = 6) with mean PCT levels of 1.26 ng/mL and 5.61 ng/mL at t0 and t1, respectively. However, we saw a higher mean serum PCT level for patients having bacteremia with Gram-negative organisms (n = 12), 5.50 ng/mL and 14.59 ng/mL at t0 and t1, respectively. This is similar to the observations of Fleischhack et al,<sup><xref ref-type="bibr" rid="bibr37-0009922812460913">37</xref></sup> who reported higher PCT levels in febrile neutropenic children infected with Gram-negative bacteria as compared with Gram-positive bacteria. Similarly, Svaldi et al<sup><xref ref-type="bibr" rid="bibr45-0009922812460913">45</xref></sup> showed increased levels of PCT with Gram-negative bacteria as compared with Gram-positive bacteria in leukopenic adults.</p>
<p>We determined the best combination of sensitivity and specificity to detect bacteremia at t0 and t1 was achieved at a cutoff value of 0.4 ng/mL. Further analysis using different cutoff values for PCT can be seen in <xref ref-type="table" rid="table3-0009922812460913">Table 3</xref>. Giamarellos-Bourboulis et al<sup><xref ref-type="bibr" rid="bibr46-0009922812460913">46</xref></sup> stated that PCT levels greater than 1 ng/mL in a single sample (t0) in febrile neutropenia should raise the suspicion for bacteremia.<sup><xref ref-type="bibr" rid="bibr46-0009922812460913">46</xref></sup> Our data showed PCT levels greater than 0.4 ng/mL to be a more sensitive marker of bacteremia when compared with 1 ng/mL (72%, 44%, respectively). At 1 ng/mL, 10 patients with bacteremia would have incorrectly tested negative as opposed to 3 patients at 0.4 ng/mL.</p>
<p>In 3 of our 4 patients whose blood cultures grew bacteria, the optimal cutoff PCT level of 0.4 ng/mL would have raised suspicion for bacteremia. Because our patient population is at risk for acute decompensation, the optimal level of PCT needs to be maximized to have a high sensitivity especially at t0 along with an acceptable specificity. This will offer the clinician the ability to intervene earlier to prevent the patient entering sepsis.</p>
<p>If we look at our initial cutoff value of 0.5 ng/mL at t0 and compare it with the optimal cutoff value of 0.4 ng/mL at t0, we obtained a 22% increase in sensitivity without compromising too much in specificity. The diagnostic characteristics of PCT on admission using 0.4 ng/mL as our optimal cutoff were determined to be sensitivity of 72%, specificity of 70%, PPV of 38%, and NPV of 91%. The sensitivity of serial PCT in this population was affected by the large number of patients with no bacterial growth who had positive PCT levels at both time points. Secmeer et al<sup><xref ref-type="bibr" rid="bibr29-0009922812460913">29</xref></sup> who also used a PCT at 0.4 ng/mL had a sensitivity of 33%, specificity of 92%, PPV of 50%, and NPV of 92%. The NPVof serial PCT levels using 0.4 ng/mL as a cutoff offered a good indication that if the blood culture has not shown growth there is 96% likelihood that the patient will not have bacteremia. Furthermore, our data showed that there was 100% sensitivity and 100% NPV to rule out bacteremia with 2 serial PCT levels less than 0.2 ng/mL.</p>
<p>One of the limitations to our study is that we did not compare our patient population’s PCT values directly with the low- and high-risk classification.<sup><xref ref-type="bibr" rid="bibr9-0009922812460913">9</xref>,<xref ref-type="bibr" rid="bibr16-0009922812460913">16</xref>,<xref ref-type="bibr" rid="bibr47-0009922812460913">47</xref>,<xref ref-type="bibr" rid="bibr48-0009922812460913">48</xref></sup> Prior to evaluating the PCT values, we felt our study population was at high risk for bacteremia because their ANC was less than 500 (mean ANC of 111). Furthermore, there is still debate on exactly who should be classified as high or low risk.<sup><xref ref-type="bibr" rid="bibr20-0009922812460913">20</xref></sup> Macher et al<sup><xref ref-type="bibr" rid="bibr20-0009922812460913">20</xref></sup> reviewed pediatric articles in attempt to provide a set of clinical predictors for bacteremia in chemotherapy-induced fever and neutropenia. Their study concluded that it was difficult to identify standardized criteria to predict bacteremia because of the numerous clinical variables in fever and neutropenia. It would be worth investigating the clinical predictors reviewed by Macher et al<sup><xref ref-type="bibr" rid="bibr20-0009922812460913">20</xref></sup> and incorporate our study’s noteworthy PCT values of 0.2 and 0.4 ng/mL to determine if these values would help with risk classification.</p>
<p>We do acknowledge that there are other laboratory values that may be used to help identify bacteremia. In this study, we did not compare our patients’ PCT values with other laboratory values such as C-reactive protein, absolute monocyte count, platelet count, or other vital signs excluding temperature. We did not include these because oftentimes the only presenting sign for bacteremia is fever. Evaluating PCT along with these values may help in the assessment of patients who are at risk for bacteremia.</p>
</sec>
<sec id="section13-0009922812460913" sec-type="conclusions">
<title>Conclusion</title>
<p>In summary, we believe that PCT in itself can be used in the early detection of bacteremia in pediatric oncology patients who present with fever and severe neutropenia. Furthermore, we demonstrated that using 2 serial PCT levels within 24 hours allowed for better detection of bacteremia when compared with the initial PCT level on admission to the hospital. The established adult cutoff value of 0.5 ng/mL may need to be lowered to prevent missed cases of bacteremia. We did show that serial PCT has a high specificity and NPV. Two PCT levels less than 0.4 ng/mL showed to have a 96% NPV, indicating a strong support for using 2 serial PCT levels to rule out bacteremia in this population. Furthermore, there was 100% sensitivity and 100% NPV to rule out bacteremia with 2 serial PCT levels less than 0.2 ng/mL. This might be of the greatest value to the patients who may be candidates for early discharge from the hospital.</p>
<p>Until there is a wide consensus for pediatric patients who are classified as high or low risk for bacteremia, clinicians will continue to admit patients with fever and neutropenia. Incorporating serial PCT levels into the routine management of these children may allow for earlier intervention by monitoring the rise in PCT values. Therefore, the routine use of serial PCT levels may prevent morbidity and mortality associated with children undergoing chemotherapy. We believe that larger studies incorporating serial PCT levels in the active management in patient care are needed to fully appreciate this biomarker’s utility and clinical effectiveness. Furthermore, studies evaluating the delta PCT value may allow earlier intervention, especially in those patients who have a noticeable rise in PCT. Monitoring serial PCT levels in a low-risk classification group may allow clinically well appearing children earlier discharge from the hospital before their blood cultures are deemed negative. This will prevent prolonged hospital stays, decrease rates of nosocomial infections, and reduce the development of antibiotic-resistant organisms.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: A research grant from Children’s Hospital Central California, Madera, CA, USA made possible for the research. No direct money received by any of the authors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922812460913">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pizzo</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient</article-title>. <source>J Pediatr</source>. <year>1981</year>:<volume>98</volume>:<fpage>341</fpage>-<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr2-0009922812460913">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irfan</surname><given-names>S</given-names></name>
<name><surname>Idrees</surname><given-names>F</given-names></name>
<name><surname>Mehraj</surname><given-names>V</given-names></name>
<name><surname>Habib</surname><given-names>F</given-names></name>
<name><surname>Adil</surname><given-names>S</given-names></name>
<name><surname>Hasan</surname><given-names>R</given-names></name>
</person-group>. <article-title>Emergence of carbapenem resistant gram negative and vancomycin resistant gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study</article-title>. <source>BMC Infect Dis</source>. <year>2008</year>;<volume>8</volume>:<fpage>80</fpage>.</citation>
</ref> <ref id="bibr3-0009922812460913">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elting</surname><given-names>LS</given-names></name>
<name><surname>Lu</surname><given-names>C</given-names></name>
<name><surname>Escalante</surname><given-names>CP</given-names></name>
<etal/></person-group>. <article-title>Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>:<fpage>606</fpage>-<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr4-0009922812460913">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hann</surname><given-names>I</given-names></name>
<name><surname>Viscoli</surname><given-names>C</given-names></name>
<name><surname>Paesmans</surname><given-names>M</given-names></name>
<name><surname>Gaya</surname><given-names>H</given-names></name>
<name><surname>Glauser</surname><given-names>M</given-names></name>
</person-group>. <article-title>A comparison of outcome from febrile neutropenic episodes in children compared with adults</article-title>. <source>Br J Haematol</source>. <year>1997</year>;<volume>99</volume>:<fpage>580</fpage>-<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr5-0009922812460913">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>WT</given-names></name>
<name><surname>Armstrong</surname><given-names>D</given-names></name>
<name><surname>Bodey</surname><given-names>GP</given-names></name>
<etal/></person-group>. <article-title>2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer</article-title>. <source>Clin Infect Dis</source>. <year>2002</year>;<volume>34</volume>:<fpage>730</fpage>-<lpage>751</lpage>.</citation>
</ref>
<ref id="bibr6-0009922812460913">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Talcott</surname><given-names>JA</given-names></name>
<name><surname>Siegel</surname><given-names>RD</given-names></name>
<name><surname>Finberg</surname><given-names>R</given-names></name>
<name><surname>Goldman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule</article-title>. <source>J Clin Oncol</source>. <year>1992</year>;<volume>10</volume>:<fpage>316</fpage>-<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr7-0009922812460913">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>SW</given-names></name>
<name><surname>Wade</surname><given-names>KC</given-names></name>
<name><surname>Hibberd</surname><given-names>PL</given-names></name>
<name><surname>Parsons</surname><given-names>SK</given-names></name>
</person-group>. <article-title>Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2002</year>;<volume>24</volume>:<fpage>38</fpage>-<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr8-0009922812460913">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ammann</surname><given-names>RA</given-names></name>
<name><surname>Hirt</surname><given-names>A</given-names></name>
<name><surname>Luthy</surname><given-names>AR</given-names></name>
<name><surname>Aebi</surname><given-names>C</given-names></name>
</person-group>. <article-title>Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection</article-title>. <source>Med Pediatr Oncol</source>. <year>2003</year>;<volume>41</volume>:<fpage>436</fpage>-<lpage>443</lpage>.</citation>
</ref>
<ref id="bibr9-0009922812460913">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ammann</surname><given-names>RA</given-names></name>
<name><surname>Hirt</surname><given-names>A</given-names></name>
<name><surname>Luthy</surname><given-names>AR</given-names></name>
<name><surname>Aebi</surname><given-names>C</given-names></name>
</person-group>. <article-title>Predicting bacteremia in children with fever and chemotherapy-induced neutropenia</article-title>. <source>Pediatric Infect Dis</source>. <year>2004</year>;<volume>23</volume>:<fpage>61</fpage>-<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr10-0009922812460913">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hakim</surname><given-names>H</given-names></name>
<name><surname>Flynn</surname><given-names>PM</given-names></name>
<name><surname>Srivastava</surname><given-names>DK</given-names></name>
<etal/></person-group>. <article-title>Risk prediction in pediatric cancer patients with fever and neutropenia</article-title>. <source>Pediatric Infect Dis</source>. <year>2010</year>;<volume>29</volume>:<fpage>53</fpage>-<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr11-0009922812460913">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holdsworth</surname><given-names>M</given-names></name>
<name><surname>Hanrahan</surname><given-names>J</given-names></name>
<name><surname>Albanese</surname><given-names>B</given-names></name>
<name><surname>Frost</surname><given-names>J</given-names></name>
</person-group>. <article-title>Outpatient management of febrile neutropenia in children with cancer</article-title>. <source>Paediatr Drugs</source>. <year>2003</year>;<volume>5</volume>:<fpage>443</fpage>-<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr12-0009922812460913">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>GR</given-names></name>
<name><surname>Konsler</surname><given-names>GK</given-names></name>
<name><surname>Dunaway</surname><given-names>RP</given-names></name>
<name><surname>Pusek</surname><given-names>SN</given-names></name>
</person-group>. <article-title>Infection risk factors in febrile, neutropenic children and adolescents</article-title>. <source>Pediatr Hematol Oncol</source>. <year>1996</year>;<volume>13</volume>:<fpage>217</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr13-0009922812460913">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kocak</surname><given-names>U</given-names></name>
<name><surname>Rolston</surname><given-names>KV</given-names></name>
<name><surname>Mullen</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemia</article-title>. <source>Support Care Cancer</source>. <year>2002</year>;<volume>10</volume>:<fpage>58</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr14-0009922812460913">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rondinelli</surname><given-names>PI</given-names></name>
<name><surname>Ribeiro Kde</surname><given-names>C</given-names></name>
<name><surname>de Camargo</surname><given-names>B</given-names></name>
</person-group>. <article-title>A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2006</year>;<volume>28</volume>:<fpage>665</fpage>-<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr15-0009922812460913">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karthaus</surname><given-names>M</given-names></name>
<name><surname>Egerer</surname><given-names>G</given-names></name>
<name><surname>Jurgens</surname><given-names>H</given-names></name>
</person-group>. <article-title>Outpatient treatment of cancer patients with fever and neutropenia</article-title>. <source>Antibiot Chemother</source>. <year>2000</year>;<volume>50</volume>:<fpage>47</fpage>-<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr16-0009922812460913">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klaassen</surname><given-names>RJ</given-names></name>
<name><surname>Goodman</surname><given-names>TR</given-names></name>
<name><surname>Pham</surname><given-names>B</given-names></name>
<name><surname>Doyle</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>“Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia</article-title>. <source>J Clin Oncol</source>. <year>2000</year>;<volume>18</volume>:<fpage>1012</fpage>-<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr17-0009922812460913">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meckler</surname><given-names>G</given-names></name>
<name><surname>Lindemulder</surname><given-names>S</given-names></name>
</person-group>. <article-title>Fever and neutropenia in pediatric patients with cancer</article-title>. <source>Emerg Med Clin North Am</source>. <year>2009</year>:<volume>27</volume>:<fpage>525</fpage>-<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr18-0009922812460913">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santolaya</surname><given-names>ME</given-names></name>
<name><surname>Alvarez</surname><given-names>AM</given-names></name>
<name><surname>Aviles</surname><given-names>CL</given-names></name>
<etal/></person-group>. <article-title>Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia</article-title>. <source>Clin Infect Dis</source>. <year>2002</year>;<volume>35</volume>:<fpage>678</fpage>-<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr19-0009922812460913">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santolaya</surname><given-names>ME</given-names></name>
<name><surname>Alvarez</surname><given-names>AM</given-names></name>
<name><surname>Aviles</surname><given-names>CL</given-names></name>
<etal/></person-group>. <article-title>Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial</article-title>. <source>Pediatric Infect Dis</source>. <year>2008</year>;<volume>27</volume>:<fpage>538</fpage>-<lpage>543</lpage>.</citation>
</ref>
<ref id="bibr20-0009922812460913">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Macher</surname><given-names>E</given-names></name>
<name><surname>Dubos</surname><given-names>F</given-names></name>
<name><surname>Garnier</surname><given-names>N</given-names></name>
<etal/></person-group>. <article-title>Predicting the risk of severe bacterial infection in children with chemotherapy-induced febrile neutropenia</article-title>. <source>Pediatr Blood Cancer</source>. <year>2010</year>;<volume>55</volume>:<fpage>662</fpage>-<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr21-0009922812460913">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pizzo</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Management of fever in patients with cancer and treatment-induced neutropenia</article-title>. <source>N Engl J Med</source>. <year>1993</year>;<volume>328</volume>:<fpage>1323</fpage>-<lpage>1332</lpage>.</citation>
</ref>
<ref id="bibr22-0009922812460913">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kara</surname><given-names>A</given-names></name>
<name><surname>Kanra</surname><given-names>G</given-names></name>
<name><surname>Cengiz</surname><given-names>AB</given-names></name>
<name><surname>Apiş</surname><given-names>M</given-names></name>
<name><surname>Gür</surname><given-names>D</given-names></name>
</person-group>. <article-title>Pediatric blood culture: time to positivity</article-title>. <source>Turk J Pediatr</source>. <year>2004</year>;<volume>46</volume>:<fpage>251</fpage>-<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr23-0009922812460913">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Towns</surname><given-names>ML</given-names></name>
<name><surname>Jarvis</surname><given-names>WR</given-names></name>
<name><surname>Hsueh</surname><given-names>PR</given-names></name>
</person-group>. <article-title>Guidelines on blood cultures</article-title>. <source>J Microbiol Immunol Infect</source>. <year>2010</year>;<volume>43</volume>:<fpage>347</fpage>-<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr24-0009922812460913">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isaacman</surname><given-names>DJ</given-names></name>
<name><surname>Karasic</surname><given-names>RB</given-names></name>
<name><surname>Reynolds</surname><given-names>EA</given-names></name>
<name><surname>Kost</surname><given-names>SI</given-names></name>
</person-group>. <article-title>Effect of number of blood cultures and volume of blood on detection of bacteremia in children</article-title>. <source>J Pediatr</source>. <year>1996</year>;<volume>128</volume>:<fpage>190</fpage>-<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr25-0009922812460913">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinstein</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Current blood culture methods and systems: clinical concepts, technology, and interpretation of results</article-title>. <source>Clin Infect Dis</source>. <year>1996</year>;<volume>23</volume>:<fpage>40</fpage>-<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr26-0009922812460913">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Avabratha</surname><given-names>KS</given-names></name>
<name><surname>Rau</surname><given-names>AT</given-names></name>
<name><surname>Venkataravanamma</surname><given-names>P</given-names></name>
<name><surname>Rau</surname><given-names>A</given-names></name>
</person-group>. <article-title>Significance of C-reactive protein during febrile neutropenia in pediatric malignancies</article-title>. <source>Indian Pediatr</source>. <year>2009</year>;<volume>46</volume>:<fpage>797</fpage>-<lpage>799</lpage>.</citation>
</ref>
<ref id="bibr27-0009922812460913">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martinez-Albarran</surname><given-names>M</given-names></name>
<name><surname>Perez-Molina Jde</surname><given-names>J</given-names></name>
<name><surname>Gallegos-Castorena</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Procalcitonin and c-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer</article-title>. <source>Pediatr Hematol Oncol</source>. <year>2009</year>;<volume>26</volume>:<fpage>414</fpage>-<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr28-0009922812460913">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miedema</surname><given-names>KG</given-names></name>
<name><surname>de Bont</surname><given-names>ES</given-names></name>
<name><surname>Elferink</surname><given-names>RF</given-names></name>
<etal/></person-group>. <article-title>The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia</article-title>. <source>Support Care Cancer</source>. <year>2011</year>;<volume>19</volume>:<fpage>1593</fpage>-<lpage>1600</lpage>.</citation>
</ref>
<ref id="bibr29-0009922812460913">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Secmeer</surname><given-names>G</given-names></name>
<name><surname>Devrim</surname><given-names>I</given-names></name>
<name><surname>Kara</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia</article-title>. <source>J Pediatr Hematol Oncol</source>. <year>2007</year>;<volume>29</volume>:<fpage>107</fpage>-<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr30-0009922812460913">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spasova</surname><given-names>MI</given-names></name>
<name><surname>Terzieva</surname><given-names>DD</given-names></name>
<name><surname>Tzvetkova</surname><given-names>TZ</given-names></name>
<etal/></person-group>. <article-title>Interleukin-6, interleukin-8, interleukin-10, and c-reactive protein in febrile neutropenia in children with malignant diseases</article-title>. <source>Folia Med (Plovdiv)</source>. <year>2005</year>;<volume>47</volume>:<fpage>46</fpage>-<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr31-0009922812460913">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunkhorst</surname><given-names>FM</given-names></name>
<name><surname>Heinz</surname><given-names>U</given-names></name>
<name><surname>Forycki</surname><given-names>ZF</given-names></name>
</person-group>. <article-title>Kinetics of procalcitonin in iatrogenic sepsis</article-title>. <source>Intensive Care Med</source>. <year>1998</year>;<volume>24</volume>:<fpage>888</fpage>-<lpage>889</lpage>.</citation>
</ref>
<ref id="bibr32-0009922812460913">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>B</given-names></name>
<name><surname>White</surname><given-names>JC</given-names></name>
<name><surname>Nylén</surname><given-names>ES</given-names></name>
<name><surname>Snider</surname><given-names>RH</given-names></name>
<name><surname>Becker</surname><given-names>KL</given-names></name>
<name><surname>Habener</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2001</year>;<volume>86</volume>:<fpage>396</fpage>-<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr33-0009922812460913">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reinhart</surname><given-names>K</given-names></name>
<name><surname>Meisner</surname><given-names>M</given-names></name>
</person-group>. <article-title>Biomarkers in the critically ill patient: procalcitonin</article-title>. <source>Crit Care Clin</source>. <year>2011</year>;<volume>27</volume>:<fpage>253</fpage>-<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr34-0009922812460913">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sakr</surname><given-names>Y</given-names></name>
<name><surname>Sponholz</surname><given-names>C</given-names></name>
<name><surname>Tuche</surname><given-names>F</given-names></name>
<name><surname>Brunkhorst</surname><given-names>F</given-names></name>
<name><surname>Reinhart</surname><given-names>K</given-names></name>
</person-group>. <article-title>The role of procalcitonin in febrile neutropenic patients: review of the literature</article-title>. <source>Infection</source>. <year>2008</year>;<volume>36</volume>:<fpage>396</fpage>-<lpage>407</lpage>.</citation>
</ref>
<ref id="bibr35-0009922812460913">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andreola</surname><given-names>B</given-names></name>
<name><surname>Bressan</surname><given-names>S</given-names></name>
<name><surname>Callegaro</surname><given-names>S</given-names></name>
<name><surname>Liverani</surname><given-names>A</given-names></name>
<name><surname>Plebani</surname><given-names>M</given-names></name>
<name><surname>Da Dalt</surname><given-names>L</given-names></name>
</person-group>. <article-title>Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department</article-title>. <source>Pediatr Infect Dis J</source>. <year>2007</year>;<volume>26</volume>:<fpage>672</fpage>-<lpage>677</lpage>.</citation>
</ref>
<ref id="bibr36-0009922812460913">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Bont</surname><given-names>ES</given-names></name>
<name><surname>Vellenga</surname><given-names>E</given-names></name>
<name><surname>Swaanenburg</surname><given-names>J</given-names></name>
<name><surname>Kamps</surname><given-names>W</given-names></name>
</person-group>. <article-title>Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever?</article-title> <source>Infection</source>. <year>2000</year>;<volume>28</volume>:<fpage>398</fpage>-<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr37-0009922812460913">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleischhack</surname><given-names>G</given-names></name>
<name><surname>Cipic</surname><given-names>D</given-names></name>
<name><surname>Juettner</surname><given-names>J</given-names></name>
<name><surname>Hasan</surname><given-names>C</given-names></name>
<name><surname>Bode</surname><given-names>U</given-names></name>
</person-group>. <article-title>Procalcitonin—a sensitive inflammation marker of febrile episodes in neutropenic children with cancer</article-title>. <source>Intensive Care Med</source>. <year>2000</year>;<volume>26</volume>(<supplement>suppl 2</supplement>):<fpage>S202</fpage>-<lpage>S211</lpage>.</citation>
</ref>
<ref id="bibr38-0009922812460913">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hatzistilianou</surname><given-names>M</given-names></name>
</person-group>. <article-title>Diagnostic and prognostic role of procalcitonin in infections</article-title>. <source>ScientificWorldJournal</source>. <year>2010</year>;<volume>10</volume>:<fpage>1941</fpage>-<lpage>1946</lpage>.</citation>
</ref>
<ref id="bibr39-0009922812460913">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kitanovski</surname><given-names>L</given-names></name>
<name><surname>Jazbec</surname><given-names>J</given-names></name>
<name><surname>Hojker</surname><given-names>S</given-names></name>
<name><surname>Gubina</surname><given-names>M</given-names></name>
<name><surname>Derganc</surname><given-names>M</given-names></name>
</person-group>. <article-title>Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>2006</year>;<volume>25</volume>:<fpage>413</fpage>-<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr40-0009922812460913">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>C</given-names></name>
<name><surname>Ignjatovic</surname><given-names>V</given-names></name>
<name><surname>Newall</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Change in serum procalcitonin (deltapct) predicts the clinical outcome of children admitted with febrile neutropenia</article-title>. <source>Br J Haematol</source>. <year>2002</year>;<volume>118</volume>:<fpage>1197</fpage>-<lpage>1198</lpage>.</citation>
</ref>
<ref id="bibr41-0009922812460913">
<label>41.</label>
<citation citation-type="web"><collab>BRAHMS PCT</collab>. <article-title>Welcome to PCT. Thermoscientific Web site</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.procalcitonin.com">http://www.procalcitonin.com</ext-link>. <access-date>Accessed February 15, 2012</access-date>.</citation>
</ref>
<ref id="bibr42-0009922812460913">
<label>42.</label>
<citation citation-type="book"><collab>Practice Management Information Corporation</collab>. <article-title><italic>ICD-9-CM: International Classification of Diseases</italic>, 9th rev</article-title>; <source>Clinical Modification</source>. <edition>6th ed.</edition> <year>2006</year>. Vols. <volume>1-3</volume>. <publisher-loc>Los Angeles, CA</publisher-loc>: <publisher-name>Practice Management Information Corporation</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr43-0009922812460913">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonsalves</surname><given-names>WI</given-names></name>
<name><surname>Cornish</surname><given-names>N</given-names></name>
<name><surname>Moore</surname><given-names>M</given-names></name>
<name><surname>Chen</surname><given-names>A</given-names></name>
<name><surname>Varman</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effects of volume and site of blood draw on blood culture results</article-title>. <source>J Clin Microbiol</source>. <year>2009</year>;<volume>47</volume>:<fpage>3482</fpage>-<lpage>3485</lpage>.</citation>
</ref>
<ref id="bibr44-0009922812460913">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Plorde</surname><given-names>JJ</given-names></name>
<name><surname>Carlson</surname><given-names>LG</given-names></name>
</person-group>. <article-title>Effects of volume and periodicity on blood cultures</article-title>. <source>J Clin Microbiol</source>. <year>1994</year>;<volume>32</volume>:<fpage>2829</fpage>-<lpage>2831</lpage>.</citation>
</ref>
<ref id="bibr45-0009922812460913">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Svaldi</surname><given-names>M</given-names></name>
<name><surname>Hirber</surname><given-names>J</given-names></name>
<name><surname>Lanthaler</surname><given-names>AI</given-names></name>
<etal/></person-group>. <article-title>Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients</article-title>. <source>Br J Haematol</source>. <year>2001</year>;<volume>115</volume>:<fpage>53</fpage>-<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr46-0009922812460913">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name>
<name><surname>Grecka</surname><given-names>P</given-names></name>
<name><surname>Poulakou</surname><given-names>G</given-names></name>
<name><surname>Anargyrou</surname><given-names>K</given-names></name>
<name><surname>Katsilambros</surname><given-names>N</given-names></name>
<name><surname>Giamarellou</surname><given-names>H</given-names></name>
</person-group>. <article-title>Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia</article-title>. <source>Clin Infect Dis</source>. <year>2001</year>;<volume>32</volume>:<fpage>1718</fpage>-<lpage>1725</lpage>.</citation>
</ref>
<ref id="bibr47-0009922812460913">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baorto</surname><given-names>EP</given-names></name>
<name><surname>Aquino</surname><given-names>VM</given-names></name>
<name><surname>Mullen</surname><given-names>CA</given-names></name>
<name><surname>Buchanan</surname><given-names>GR</given-names></name>
<name><surname>DeBaun</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia</article-title>. <source>Cancer</source>. <year>2001</year>;<volume>92</volume>:<fpage>909</fpage>-<lpage>913</lpage>.</citation>
</ref>
<ref id="bibr48-0009922812460913">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rackoff</surname><given-names>WR</given-names></name>
<name><surname>Gonin</surname><given-names>R</given-names></name>
<name><surname>Robinson</surname><given-names>C</given-names></name>
<name><surname>Kreissman</surname><given-names>SG</given-names></name>
<name><surname>Breitfeld</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Predicting the risk of bacteremia in children with fever and neutropenia</article-title>. <source>J Clin Oncol</source>. <year>1996</year>;<volume>14</volume>:<fpage>919</fpage>-<lpage>924</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>